What Novartis actually looks for
Novartis, headquartered in Basel, Switzerland, was formed in 1996 from the merger of Ciba-Geigy and Sandoz, and in 2023 the company spun off its generics and biosimilars unit as an independent, separately listed Sandoz, leaving Novartis focused specifically on innovative, patent-protected medicines. Its portfolio includes Entresto for heart failure, Cosentyx for psoriasis and psoriatic arthritis, Kisqali for breast cancer, and Zolgensma, a gene therapy for spinal muscular atrophy that remains one of the most expensive single-dose treatments ever approved, which makes pricing and access a genuine topic in commercial and policy-adjacent interviews. Since the Sandoz spinoff, Novartis has repositioned itself as a leaner, more focused innovative-medicines company, and interviewers often want to know you understand what that strategic narrowing means for R&D prioritization and pipeline risk. Expect a research-driven culture that values scientific rigor and regulatory precision given the company's global footprint across more than 100 countries.
Common questions and how to answer them
How has the Sandoz spinoff changed Novartis's strategic focus? A strong answer explains that Novartis now concentrates fully on innovative, higher-margin medicines rather than splitting attention across generics, and ties this to specific franchises like Entresto or Kisqali. How would you think about pricing a therapy like Zolgensma, where a single dose costs an extraordinary amount? This tests your ability to reason about value-based pricing and patient access simultaneously, rather than picking one side; reference outcomes-based payment models as a real industry approach. Tell me about a time you had to make a decision with significant regulatory or compliance implications. Pharma interviewers weigh judgment under regulatory constraint heavily; use a specific, real example showing you understand consequences beyond the immediate business outcome. Across all three, be ready to name a specific Novartis drug and its therapeutic area, since vague references to the pipeline signal a lack of real preparation.
How to prepare
Understand the Sandoz spinoff and what it signals about Novartis's current strategy: fewer, higher-value innovative medicines rather than a broad generics-plus-branded portfolio. Know at least two or three major franchises by name and therapeutic area, such as Entresto (heart failure), Cosentyx (immunology), and Kisqali (oncology), since generic pharma knowledge won't hold up under specific questioning. If interviewing for a Basel-based role, be aware Novartis operates in a genuinely international, multilingual environment, and cross-border regulatory fluency is valued. Expect a structured, multi-stage process that may include a case interview for commercial roles and a scientific presentation for R&D roles, reflecting the company's rigorous, process-driven culture.